A Pilot Study of the Neo-adjuvant Use of Vemurafenib in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastasis.
This study will evaluate the clinical and pathological response to vemurafenib and
cobimetinib in the neoadjuvant treatment of patients with histologically confirmed, BRAF
V600 mutation-positive Stage IIIB and C melanoma. 20 patients will be treated with
vemurafenib and cobimetinib for 2 months. Then they will be assessed for surgery. Patients
will undergo surgery and subsequently resume taking vemurafenib and cobimetinib after
recovery from surgery. Patients will undergo radiation therapy if appropriate then continue
vemurafenib and cobimetinib. The maximum treatment period is 12 months. After 12 months of
treatment, patients will be followed for disease recurrence and survival during for a total
of 5 years.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society